RxDoctor Payments Data

Emie Kuyumjian, MD

Family Medicine · Cape Coral, FLNPI 1962602482

Payments from drug & device makers

$9,705in general payments, 2019–2025

Across 574 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Novo Nordisk$1K
  • Johnson & Johnson$806
  • Amgen$669
  • Astellas Pharma US Inc$596
  • Pfizer$520
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$9,51298%
  • Education$1932%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,705 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$409,757
Medicare patients
569
Services billed
12,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin160$240,157
EliquisApixaban174$217,327
MounjaroTirzepatide143$180,856
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$134,654
OzempicSemaglutide43$55,027
XareltoRivaroxaban43$54,798
ProliaDenosumab18$31,694
FarxigaDapagliflozin Propanediol19$30,531
MyrbetriqMirabegron21$22,936
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$15,315
LinzessLinaclotide12$14,162
Tresiba Flextouch U-200Insulin Degludec12$12,080
SynthroidLevothyroxine Sodium134$11,292
SymbicortBudesonide/Formoterol Fumarate17$10,231
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen277$7,717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$224$240,157160 claims
PfizerEliquis, Paxlovid$520$220,108204 claims
Lilly USA, LLCMounjaro$425$180,856143 claims
GSKTrelegy Ellipta$1,641$134,65491 claims
Novo NordiskOzempic$1,215$55,02743 claims
Johnson & JohnsonXarelto$806$54,79843 claims
AstraZenecaFarxiga, Symbicort$284$40,76236 claims
AmgenProlia$669$31,69418 claims
AbbVieLinzess, Synthroid$499$25,454146 claims
Astellas Pharma US IncMyrbetriq$596$22,93621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Cape Coral

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →